TNBC poses significant therapeutic challenges due to its aggressive nature, lack of hormone receptors, and absence of HER2 overexpression, which limit the efficacy of targeted therapies commonly used in other breast cancer subtypes. This evidence concerns the gene NR4A1 and breast carcinoma.